Skip to Content
Merck
  • Prediction of preterm birth with and without preeclampsia using mid-pregnancy immune and growth-related molecular factors and maternal characteristics.

Prediction of preterm birth with and without preeclampsia using mid-pregnancy immune and growth-related molecular factors and maternal characteristics.

Journal of perinatology : official journal of the California Perinatal Association (2018-05-26)
Laura L Jelliffe-Pawlowski, Larry Rand, Bruce Bedell, Rebecca J Baer, Scott P Oltman, Mary E Norton, Gary M Shaw, David K Stevenson, Jeffrey C Murray, Kelli K Ryckman
ABSTRACT

To evaluate if mid-pregnancy immune and growth-related molecular factors predict preterm birth (PTB) with and without (±) preeclampsia. Included were 400 women with singleton deliveries in California in 2009-2010 (200 PTB and 200 term) divided into training and testing samples at a 2:1 ratio. Sixty-three markers were tested in 15-20 serum samples using multiplex technology. Linear discriminate analysis was used to create a discriminate function. Model performance was assessed using area under the receiver operating characteristic curve (AUC). Twenty-five serum biomarkers along with maternal age <34 years and poverty status identified >80% of women with PTB ± preeclampsia with best performance in women with preterm preeclampsia (AUC = 0.889, 95% confidence interval (0.822-0.959) training; 0.883 (0.804-0.963) testing). Together with maternal age and poverty status, mid-pregnancy immune and growth factors reliably identified most women who went on to have a PTB ± preeclampsia.

MATERIALS
Product Number
Brand
Product Description

Millipore
MILLIPLEX® Human Soluble Cytokine Receptor Panel, HSCRMAG-32K- Immunology Multiplex Assay, Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.